if sending her home is the right decision…
that it is.
Improve patient care and reduce unnecessary interventions
Fetal fibronectin (fFN) testing can help reduce unnecessary admissions and interventions.1 Multiple studies over the last two decades show that implementing a standard preterm labor protocol that includes fFN testing can help improve outcomes and optimize resources.
The Rapid fFN® test has the best sensitivity to help rule out preterm labor1,2
Determining which patients are in true preterm labor is a challenge.
fFN testing can help rule out ~80% of them.1
Multiple studies have repeatedly shown that clinical assessment and cervical length alone cannot reliably rule out imminent preterm birth in patients. Adding fFN testing to clinical assessment and cervical length can dramatically improve preterm birth prediction by as much as 50%.3
fFN is an indicator of preterm birth
Fetal fibronectin (fFN) acts as an adhesive glycoprotein at the maternal-fetal interface that helps “glue” the baby to the uterus.1 It should be absent in vaginal secretions between 16-35 weeks.4 Its premature presence in vaginal secretions is a direct biochemical predictor of preterm birth risk. fFN is the single common biochemical marker for all 4 mechanisms of preterm birth: activation of the maternal/fetal hypothalamic-pituitary-adrenal (HPA) axis, inflammation, decidual hemorrhage and pathological uterine distention.5
When fFN is “leaking” into the vagina during weeks 22 to 35 of gestation and detectable at higher levels, the Rapid fFN test returns a positive result. This indicates there is some type of disruption and the patient is at an increased risk of early delivery.1
When there is an absence of fFN in vaginal secretions, the Rapid fFN test returns a negative result. This serves as a reassuring indicator that the pregnancy is progressing normally.1
Contact us for more information about the Rapid fFN® test.